



## Product Information

**Product ID** P7608

**CAS No.** 775304-57-9

**Chemical Name**

**Synonym** PTC-124, Ataluren, Translarna™

**Formula** C<sub>15</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>3</sub>

**Formula Wt.** 284.25

**Melting Point**


**Purity** ≥98%

**Solubility** DMSO 57 mg/mL (200mM)  
Water Insoluble  
Ethanol Insoluble

**Store Temp** -20°C

**Ship Temp** Ambient

**Description** PTC124 allows read-through of premature stop codons in mRNA, enabling proper protein translation. This compound is used to treat Duchenne muscular dystrophy (DMD) and cystic fibrosis as well as other nonsense mutation disorders.



## Pricing and Availability

**Bulk quantities available upon request**

Product ID	Size	List Price
P7608	5 mg	\$55.80
P7608	25 mg	\$198.20
P7608	100 mg	\$476.90

**References** Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle Nerve*. 2014 Oct;50(4):477-87. PMID: 25042182.

Ryan NJ. Ataluren: first global approval. *Drugs*. 2014 Sep;74(14):1709-14. PMID: 25193627.

Nagel-Wolfrum K, Möller F, Penner I, et al. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations. *Vis Neurosci*. 2014 Sep;31(4-5):309-16. PMID: 24912600.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.